Drug Profile
Imsidolimab - AnaptysBio
Alternative Names: ANB 019Latest Information Update: 11 Oct 2023
Price :
$50
*
At a glance
- Originator AnaptysBio
- Class Anti-inflammatories; Antibodies; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 36 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pustular psoriasis
Highest Development Phases
- Phase III Generalised pustular psoriasis
- Phase II Acneiform eruptions; Ichthyosis
- No development reported Palmoplantar pustulosis
- Discontinued Acne vulgaris; Hidradenitis suppurativa
Most Recent Events
- 09 Oct 2023 AnaptysBio plans to file a biologics license application (BLA) for Generalized Pustular Psoriasis with the US FDA by Q3 2024.
- 09 Oct 2023 Adverse events and efficacy data from the phase III GEMINI1 trial in Generalised pustular psoriasis released by AnaptysBio
- 17 Aug 2023 AnaptysBio completes the phase III GEMINI1 trial in Generalised pustular psoriasis in Australia, Georgia, Germany, South Korea, Malaysia, Morocco, Poland, Romania, Slovakia, Spain, Taiwan, Thailand, Tunisia, Turkey, USA (IV) (NCT05352893) (EudraCT2021-001447-27)